Scancell Holdings plc (LON:SCLP – Get Free Report)’s stock price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 10.42 ($0.13) and traded as low as GBX 10.13 ($0.13). Scancell shares last traded at GBX 10.50 ($0.13), with a volume of 554,868 shares trading hands.
Scancell Stock Performance
The company’s 50 day moving average is GBX 9.97 and its 200-day moving average is GBX 10.42. The firm has a market capitalization of £97.54 million, a P/E ratio of -1,050.00 and a beta of 0.37. The company has a quick ratio of 13.01, a current ratio of 8.63 and a debt-to-equity ratio of 61.41.
Scancell Company Profile
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer.
Featured Articles
- Five stocks we like better than Scancell
- Insider Selling Explained: Can it Inform Your Investing Choices?
- RXO Shares Surge Following New Acquisition Deal
- Canada Bond Market Holiday: How to Invest and Trade
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- CD Calculator: Certificate of Deposit Calculator
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.